(RTTNews) - GH Research PLC (GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, announced ...
In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on GH Research (GHRS – Research Report), with a price target of $39.00. The company’s shares opened today ...
Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on GHRS stock, giving a Buy rating yesterday. Discover outperforming stocks and invest smarter with Top Smart Score Stocks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback